beroterkib

Beroterkib is an orally bioavailable small molecule inhibitor targeting extracellular signal-regulated kinases 1 and 2 (ERK1/2), which are key components of the MAPK signaling pathway. It is being developed as an antineoplastic agent for the treatment of advanced or refractory solid tumors, including melanoma, myelodysplastic syndrome, chronic myeloid leukemia, chronic myelomonocytic leukemia, and non-small cell lung cancer. The drug was initially developed by Astex Pharmaceuticals and is currently under clinical development by Taiho Pharmaceutical. Beroterkib acts by inhibiting ERK1/2 activity to disrupt tumor cell proliferation and survival[1][2][3][5][7].

Other names

beroterkib hydrateberoterkib anhydrous